Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis
There is a group of MG patients that suffers from persistent symptoms and exacerbations (11%-20%) or MG crises, and drug AEs, which may increase disease burden and impact on the healthcare system.
Authors
- Elena Cortés‐Vicente (ORCID: https://orcid.org/0000-0002-1428-1072)
- Ana Vesperinas‐Castro
- Luís Querol (ORCID: https://orcid.org/0000-0002-4289-8264)
- Montse Olivé (ORCID: https://orcid.org/0000-0001-5727-0165)
- Ricard Rojas‐García (ORCID: https://orcid.org/0000-0003-1411-5573)
- David Reyes‐Leiva (ORCID: https://orcid.org/0000-0001-6983-7130)
- Janina Turón‐Sans (ORCID: https://orcid.org/0000-0002-8842-4646)
- Francesc Pla‐Juncà (ORCID: https://orcid.org/0000-0002-4403-6297)
- Eduard Gallardo (ORCID: https://orcid.org/0000-0002-3942-3436)
- Álvaro Carbayo (ORCID: https://orcid.org/0000-0001-9282-8603)
- Mar Pujades‐Rodríguez (ORCID: https://orcid.org/0000-0002-1375-1028)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital de Sant Pau (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Centro de Investigación Biomédica en Red (ES)
- Institut de Recerca Sant Pau (ES)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1111/ene.16463
- Citations
- 8
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.95
Funders
- UCB
- Instituto de Salud Carlos III